RecruitingPhase 1Phase 2NCT06885281
A Study of ZL-1310 in Participants With Selected Solid Tumors
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Sponsor
Zai Lab (Shanghai) Co., Ltd.
Enrollment
166 participants
Start Date
May 12, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called ZL-1310 for people with solid tumors. The study is currently recruiting participants at 21 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGZL-1310
drug ZL-1310
Locations(23)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06885281
Related Trials
A Study of DS3610a in Participants With Advanced Solid Tumor
NCT071591262 locations
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
NCT033661161 location
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873780 locations
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT0749268057 locations
REC-7735 in Participants With Solid Tumors
NCT07819136